Nasdaq · Healthcare
NEXGEL, INC. (NXGL)
As-reported financials and recent SEC filings for NEXGEL, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$11.4M
Net income
$-3.0M
Net margin
-26.3%
Diluted EPS
$-0.38
ROE
-61.3%
P/E (TTM)
—
Market cap
—
Debt / equity
0.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $11.4M | $8.7M | $4.1M | $2.0M | $1.6M |
| Gross profit | $4.5M | $2.7M | $374,000 | $256,000 | $8,000 |
| Operating income | $-3.4M | $-3.6M | $-3.5M | $-3.3M | $-2.6M |
| Net income | $-3.0M | $-3.3M | $-3.2M | $-4.7M | $-4.3M |
| Diluted EPS | $-0.38 | $-0.50 | $-0.56 | $-0.85 | $-1.45 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-07-02
View on EDGAR →42026-06-23
View on EDGAR →8-K2026-06-17
View on EDGAR →42026-06-15
View on EDGAR →42026-06-09
View on EDGAR →DEF 14A2026-06-09
View on EDGAR →42026-06-03
View on EDGAR →42026-05-29
View on EDGAR →Largest Healthcare peers
Go deeper on NXGL
Search NEXGEL, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.